Standout Papers

Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bl... 2012 2026 2016 2021 319
  1. Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial (2012)
    Vik Khullar, G. Amarenco et al. European Urology

Immediate Impact

34 standout
Sub-graph 1 of 16

Citing Papers

Deep Convolutional Neural Networks in Medical Image Analysis: A Review
2025 Standout
Diabetic neuropathy: cutting-edge research and future directions
2025 Standout
2 intermediate papers

Works of M. Wooning being referenced

Study design of a phase 2 clinical trial with a disease-modifying Osteoarthritis drug candidate GLPG1972/S201086: The roccella trial
2020
Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 Trial
2012 Standout

Author Peers

Author Last Decade Papers Cites
M. Wooning 447 327 248 7 484
Asha Paireddy 410 334 265 11 442
Philip E.V.A. van Kerrebroeck 429 360 150 15 510
Allam Fakhoury 416 312 166 10 442
Joseph Wang 412 328 220 8 454
Jon D. Morrow 472 430 249 16 511
Ursula Ebinger 409 357 245 12 522
Martha Roach 380 311 250 7 475
Gary Hoel 458 254 110 18 502
H. Burgdörfer 510 417 145 13 562
Michael Lieber 226 287 61 8 443

All Works

Loading papers...

Rankless by CCL
2026